• Board of Eloxx Pharmaceuticals unanimously adopted resolutions that were later ratified by majority shareholder written consent dated April 28, 2026.
• Capital actions authorized include reverse stock split of common stock within 1-for-2 to 1-for-20 range, with final ratio set by board any time before April 28, 2027.
• Certificate of incorporation amendment also authorizes cut in common stock authorized shares to 100,000,000 from 500,000,000, with timing set by board before April 28, 2027.
• Equity incentive changes adopted include raising 2018 plan share pool to 20,000,000 shares, extending plan evergreen feature, raising incentive stock option share limit to 80,000,000 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eloxx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-214720), on May 08, 2026, and is solely responsible for the information contained therein.